eCite Digital Repository
Does aspirin prevent incident heart failure in healthy older adults? Examining the evidence from the ASPREE trial
Zhou, Z and Nelson, M and Ernst, ME and Reid, C and McNeil, J and Tonkin, A, ASPREE Investigator Group, Does aspirin prevent incident heart failure in healthy older adults? Examining the evidence from the ASPREE trial, Circulation: Heart Failure, 15, (6) pp. 629-631. ISSN 1941-3289 (2022) [Refereed Article]
Copyright 2022 American Heart Association, Inc.
Heart failure (HF) is now the leading cause of a first major cardiovascular event and the most common hospital discharge diagnosis in older adults. A recent cohort study by Mujaj et al included 30 000 individuals at risk for HF (mean age, 67 years), of whom 26% had a history of coronary artery disease. The analysis demonstrated an increased risk of HF in those taking aspirin (adjusted hazard ratio [HR], 1.26 [95% CI, 1.12–1.41]) but highlighted the need for evidence from randomized trials.2 ASPREE (Aspirin in Reducing Events in the Elderly (URL: https://www.clinicaltrials.gov; Unique identifier: NCT01038583) was a double-blinded, randomized, placebo-controlled trial of aspirin in healthy older subjects.
|Item Type:||Refereed Article|
|Keywords:||aspirin, heart failure, elderly, primary prevention|
|Research Division:||Biomedical and Clinical Sciences|
|Research Group:||Cardiovascular medicine and haematology|
|Research Field:||Cardiology (incl. cardiovascular diseases)|
|Objective Group:||Clinical health|
|Objective Field:||Efficacy of medications|
|UTAS Author:||Zhou, Z (Dr Zhen Zhou)|
|UTAS Author:||Nelson, M (Professor Mark Nelson)|
|Deposited By:||Menzies Institute for Medical Research|
Repository Staff Only: item control page